While Repligen Corp. has underperformed by -2.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RGEN fell by -0.20%, with highs and lows ranging from $211.13 to $110.45, whereas the simple moving average fell by -1.43% in the last 200 days.
On December 04, 2023, The Benchmark Company Downgraded Repligen Corp. (NASDAQ: RGEN) to Hold. A report published by Wells Fargo on July 20, 2023, Initiated its previous ‘Overweight’ rating for RGEN. JP Morgan also rated RGEN shares as ‘Overweight’, setting a target price of $220 on the company’s shares in an initiating report dated July 05, 2023. The Benchmark Company Initiated an Buy rating on March 28, 2023, and assigned a price target of $230. Deutsche Bank initiated its ‘Hold’ rating for RGEN, as published in its report on December 14, 2022. RBC Capital Mkts’s report from December 07, 2022 suggests a price prediction of $190 for RGEN shares, giving the stock a ‘Sector Perform’ rating. UBS also rated the stock as ‘Buy’.
Analysis of Repligen Corp. (RGEN)
Further, the quarter-over-quarter decrease in sales is -16.61%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Repligen Corp.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 2.14% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.75, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 525.99K can be a very valuable indicator of volatility for RGEN stock. On a monthly basis, the volatility of the stock is set at 3.18%, whereas on a weekly basis, it is put at 3.94%, with a gain of 4.27% over the past seven days. Furthermore, long-term investors anticipate a median target price of $210.98, showing growth from the present price of $167.86, which can serve as yet another indication of whether RGEN is worth investing in or should be passed over.
How Do You Analyze Repligen Corp. Shares?
The USA based company Repligen Corp. (RGEN) is one of the biggest names in Medical Instruments & Supplies. When comparing Repligen Corp. shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 232.91, there is a growth in quarterly earnings of -153.51%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.02%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 105.05% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RGEN shares are owned by institutional investors to the tune of 105.05% at present.
